The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy
Abstract
OBJECTIVE: To elucidate the common and distinct clinical features of immune-mediated necrotising myopathy (IMNM), also known as necrotising autoimmune myopathy associated with autoantibodies against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). METHODS: We examined a cohort of 460 patients with idiopathic inflammatory myopathies (IIMs) through a muscle biopsy-oriented registration study in Japan. Study entry was strictly determined by the comprehensive histological assessment to exclude other neuromuscular disorders. Anti-SRP and anti-HMGCR antibodies were detected by RNA immunoprecipitation and ELISA, respectively. RESULTS: Of 460 patients with IIM, we diagnosed 73 (16%) as having inclusion body myositis (IBM). Of 387 patients with IIMs other than IBM, the frequencies of anti-SRP and anti-HMGCR antibodies were 18% and 12%, respectively. One patient had both autoantibodies. Severe limb muscle weakness, neck weakness, dysphagia, respiratory insufficiency and muscle atrophy were more frequently observed in patients with anti-SRP antibodies than in those with anti-HMGCR antibodies. Serum creatine levels were markedly higher in the patients with autoantibodies than in those without. Histology was characterised by necrosis and regeneration of muscle fibres and was consistent with IMNM except in 1 HMGCR-positive IBM patient. Most patients were initially treated with corticosteroids; however, additional immunosuppressive drugs were required, especially in the patients with anti-SRP antibodies. Rates of unsatisfactory neurological outcome were similar in the 2 autoantibody groups. CONCLUSIONS: Anti-SRP antibodies are associated with severe neurological symptoms, more so than are anti-HMGCR antibodies. Although these autoantibodies are independent serological markers associated with IMNM, patients bearing either share common characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polymyositis and Dermatomyositis: (First of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502132920706 · Cited by 5,059
Hoogendijk, J. E., Amato, A. A., Lecky, B. R., Choy, E. H., Lundberg, I. E., Rose, M. R., Vencovsky, J., de Visser, M., & Hughes, R. A. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.02.006 · Cited by 950
Dalakas, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1402225 · Cited by 790
Mammen, A. L., Chung, T., Christopher-Stine, L., Rosen, P., Rosen, A., Doering, K. R., & Casciola-Rosen, L. A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30156 · Cited by 699
Christopher‐Stine, L., Casciola‐Rosen, L. A., Hong, G., Chung, T., Corse, A. M., & Mammen, A. L. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27572 · Cited by 512
Polymyositis: An overdiagnosed entity
van der Meulen, M. F. G., Bronner, I. M., Hoogendijk, J. E., Burger, H., van Venrooij, W. J., Voskuyl, A. E., Dinant, H. J., Linssen, W. H. J. P., Wokke, J. H. J., & de Visser, M. (2003) · Neurology · doi:10.1212/wnl.61.3.316 · Cited by 332
Allenbach, Y., Drouot, L., Rigolet, A., Charuel, J. L., Jouen, F., Romero, N. B., Maisonobe, T., Dubourg, O., Behin, A., Laforet, P., et al. (2014) · Medicine · doi:10.1097/md.0000000000000028 · Cited by 278
Werner, J. L., Christopher‐Stine, L., Ghazarian, S. R., Pak, K. S., Kus, J. E., Daya, N. R., Lloyd, T. E., & Mammen, A. L. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34673 · Cited by 255
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy
Kassardjian, C. D., Lennon, V. A., Alfugham, N. B., Mahler, M., & Milone, M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1207 · Cited by 240
Valiyil, R., Casciola‐Rosen, L., Hong, G., Mammen, A., & Christopher‐Stine, L. (2010) · Arthritis Care & Research · doi:10.1002/acr.20219 · Cited by 236
Cited by
224th ENMC International Workshop:
Allenbach, Y., Mammen, A. L., Benveniste, O., Stenzel, W., Allenbach, Y., Amato, A., Aussey, A., Benveniste, O., De Bleecker, J., de Groot, I., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.09.016 · Cited by 582
Self-citationClassification and management of adult inflammatory myopathies
Selva-O'Callaghan, A., Pinal-Fernandez, I., Trallero-Araguás, E., Milisenda, J. C., Grau-Junyent, J. M., & Mammen, A. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30254-0 · Cited by 430
Complement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
Immune-mediated necrotizing myopathy: clinical features and pathogenesis
Allenbach, Y., Benveniste, O., Stenzel, W., & Boyer, O. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00515-9 · Cited by 335
Immune-Mediated Necrotizing Myopathy
Pinal-Fernandez, I., Casal-Dominguez, M., & Mammen, A. L. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0732-6 · Cited by 297
Metadata
- Authors
- Watanabe, Y., Uruha, A., Suzuki, S., Nakahara, J., Hamanaka, K., Takayama, K., Suzuki, N., & Nishino, I.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2016-05-04
- Volume
- 87
- Issue
- 10
- Pages
- 1038-1044
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2345360588
- Cited by
- 326
- References
- 22
- FWCI
- 29.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. https://app.cochat.ai/papers/10.1136/jnnp-2016-313166
- The paper
- Watanabe, Y., Uruha, A., Suzuki, S., Nakahara, J., Hamanaka, K., Takayama, K., Suzuki, N., & Nishino, I. (2016). Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2016-313166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.